RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Horizon 2020 proposal on 'Novel Arthritis Treatment with focus on natural Chitin Oligosaccharides'.

assistant: **Innovation**

Osteoarthritis (OA) is one of the leading causes of global disability, especially among the Elderly populations – approximately 10–12% of the adult population in the world has symptomatic OA. Specifically, it affects more than 40 million people in Europe.  Currently there is no cure for OA – there are no current therapies available that can reverse or halt the progression of osteoarthritis. OA's control strategy mainly consists of palliative pain treatment as there are several medicines on the market can alleviate pain and improve function in OA patients (e.g. analgesics, NSAIDs, opioids). Genis offers a revolutionary approach for the resolution of inflammation and tissue regeneration for OA patients - SIMECOS. SIMECOS is a biocompatible and bioactive drug, derived from Genis' patented food supplement BenectaTM , which provides less risk of side effects, reduced patient recovery time, protection of articular tissues, reduced scar tissue formation and increased success rate for treating OA disease.Genis' approach has been validated in a relevant environment (in vivo and in vitro studies) supported by Pre-Clinical and Phase I Clinical trials for BenectaTM, showing safety of the compound and its pronounced effect of resolution of inflammation and tissue regeneration.Genis is a small innovative biotechnology company from Siglufjörður, Iceland, whose aim is to discover, develop and commercialize novel and life changing pharmaceutical products, supplements and medical devices derived from crustacean exoskeletons. With their novel biocompatible and bioactive drug SIMECOS they seek to disrupt the pharmaceutical market for OA's treatment, and to access a more than €45 billion market in Europe.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain the overall concept, methodology and approach for the project 'Development of influenza delNS1 virus as a vector for foreign antigens' (2002-2006).

assistant: **Concept**

This project targets at combating diseases such as influenza and SARS. We propose to develop the influenza delNSl virus as a vector for antigens of foreign pathogens such as the SARS-associated coronavirus (SARS-CoV) and influenza virus. Candidate vaccines expressing SARS-CoV antigens as well as candidate vaccines expressing influenza virus antigens will be developed and tested in phase I clinical trials.An important feature of the delNSl vector is, that deleting the pathogenicity factor NS1 not only leads to an attenuated phenotype but also results in stimulating an efficient immune response in the host. These are highly advantageous properties for a vaccine vector. In the case of the chimeric influenza delNS 1 vaccine, expressing antigens from different influenza types by the delNSl vector would eliminate the current need to combine three different influenza virus strains for vaccination. Therefore, production and purification costs will be significantly reduced, resulting in a cheaper vaccine.The complementary constellation, the quality of the partners, efficient project management and availability of the combined resources will enable to successfully reach the goals of this project. It will allow the SMEs to significantly shorten the time necessary for the preclinical development phase and will bring the proposed chimeric vaccine viruses a major step closer to a marketable stage. Therefore, the project will contribute to the integration of partners in European research networks and, by its highly innovative features strengthen the European research.Through the involvement of partners from the Czech republic and from Slovenia this project contributes to the integration of future member countries. Due to the enormous market potential, significant earnings can be expec
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an impact statement for 'Cleaner Technology Performance Indicators for SMEs', explaining its relevance to EU policy priorities under Fourth Framework.

assistant: **Impact**

The proposed project focuses on developing of a knowledge based tool (not plain indicators) to support the decision process, and to overcome the data and information constraints that, the SMEs generally have. This project is a continuation of the recent research accomplished by the lead researcher and a major portion of this project study will form the basis of Doctoral Research (Ph. D.) of the Lead Researcher and at least one co-researcher. In addition the project objectives are the outcome of the strong recommendations of the above mentioned research work. The following project is intended to assist SMEs in improving their energy and material use efficiencies, and on reducing the pollution discharges to the environment (land, air and water). At the same time the objective is to assure the competitiveness of the European SMEs in the global market. The tools that the project intends to use, to develop Cleaner Technology Performance Indicators (CTPI) are Technology Assessment, Benchmarking, Process Optimisation, Cause analysis and Technology Management. The strategies adapted in the project, aims to get the SMEs on-board the journey of continuous (environmental performance) improvement. The project assumes that sector specific information is easy for SMEs to understand and helps them to comprehend/interpret the context of information provided. Thus the sector-specific information induces fast multiplier effect. Furthermore, there exists an overload of the generic information on CP and CT etc. that is difficult to comprehend and bring in use, specially by SMEs, where the manpower and resources are very limited. A simplified method for assessing the performance and then to interpret the performance to implement changes will overcome such a barrier and would stimulate SMEs
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the specific objectives and expected outcomes for 'Towards the neW era of 1.6 Tb/s System-In-Package transceivers for datacenter appLIcations exploiting wafer-scale co-inteGration of InP membranes and InP-HBT elecTronics' in the context of a Horizon 2020 call.

assistant: **Objectives**

IoT, 5G and cloud applications have created a huge growth of datacentre traffic fuelling the market of 400GbE and the ratification of 800GbE and 1.6T standards expected within 2013-2025. Datacentre operators must keep pace with the increasing speeds and to cope with the increasing power consumption required for airflow management and cooling. Moreover, they must address the massive interconnectivity between servers and switches dictated by 5G ultra-low latency applications. 100Gb/s per lane is the next step for the realization of 800GbE modules but this will be the end of pluggables and the start of co-packaged optics with ASICs paving the way to 1.6T and beyond. TWILIGHT aims to bring InP membranes and InP-HBT electronics at unprecedently close distances (<20um) to unleash the speed capabilities of its high performance components and to enable 112Gbaud per lane. Wafer-scale bonding together with high-accuracy assembly and co-packaging concepts, TWILIGHT’s optoelectronic engines will be capable of up to 1.6T capacity. Selective area growth will be exploited to develop C-band and O-band EMLs and UTC photodiodes in combination with echelle gratings on the same system-on-chip platform. Adaptation of the SAG layerstack will be used to develop polarization insensitive SOAs enabling complex functionalities on chip. TWILIGHT will leverage analog bandwidth interleaving for interfacing its transceivers with next generation 112G SERDES and will develop analog (de)multiplexers, >110GHz linear drivers and 100GHz TIAs. TWILIGHT will exploit the PI-SOAs to develop 4x4 and16x16 optical space switches exhibiting nanosecond latency and >50% smaller footprint. The O-band and C-band SiP transceiver demonstrators leverage up to 72% and 74% power consumption savings compared to established
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Development of accurate intermolecular potentials - improving the description of the short-range terms' demonstrating excellence, impact and implementation quality for a Fourth Framework call.

assistant: **Abstract**

We propose to obtain accurate expressions for the short range intermolecular interaction energy, as far as possible in terms of one-molecule properties, and to develop a database of such properties that can be used in intermolecular potentials for new systems . The repulsive interaction energy between two molecules will be obtained from the repulsion between each molecuLe and some suitable test particle, calculated taking correlation corrections into account. A model orientation-dependent atom-atom potential will be fitted to the calculated energy. A suitabLe combining rule will be used to obtain the molecule-molecule interaction from molecule-probe and probe-probe interactions, and it will then be refined using perturbation calculations for the complex. In this way we can compile a database of potentials that can be used in any of the applications where the current generation of crude point-charge/Lennard-Jones potentials are used, but that should give much better results.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'Research Data Alliance - Europe 3' goes beyond current state-of-the-art under Horizon 2020.

assistant: **Innovation**

The Research Data Alliance (RDA) is rapidly building the social and technical bridges that enable open sharing and re-use of data on a global level. RDA/Europe - the European plug-in to the global Research Data Alliance activities – will ensure that European research, industrial, e-infrastructure and policy stakeholders are all aware of its achievements, engaged with and actively involved in the global RDA activities and will advance the use of its results. European domain scientists and data scientists are involved in and driving a series of working and interest groups, generating first results of RDA and this momentum should be maintained and even increased. A collaborative web platform, currently under strong development, is widely used by the RDA members and coordinating administration. RDA Europe will look for innovative ways of facilitating the take-up and implementation of RDA outputs in Europe, both in academia and industry, and will continue to develop and maintain the RDA web-based collaboration framework. Further steps will be taken in steering, planning and implementing the sustainability of RDA through a legal entity, established in Europe, and investigating the most appropriate business models for long term sustainability. This RDA/Europe proposal will mainly build on the successful consortium of the previous years but strengthen its anchoring at policy, scientific and industrial uptake to drive forward RDA Europe objectives that are all grounded in technological excellence and innovation and have clear international ties. RDA Europe partners are very actively involved in the strategic planning, implementation, marketing & communication of RDA through the governance bodies of RDA.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an executive summary for the EU project 'ADVANCED MATERIALS AND PROCESSING IN ORGANIC ELECTRONICS' (MADRAS) targeting Horizon 2020.

assistant: **Abstract**

MADRAS project aims to demonstrate a materials-driven improvement of OLAE devices, establishing a high speed manufacturing methodology in a scalable competitive process which is In Mold Hybrid Printed Electronics (IMHyPE).Four high performance materials to be developed in MADRAS tackle high cost, instability and short lifetime of OLAE devices under operational conditions through the development of robust alternatives and innovative approaches. Such materials are a conductive and transparent substrate, a semiconducting transparent ink based on organic components, a transparent conductive silver nanowire-based ink and a semiconductor ink based on metal oxide nanoparticles.MADRAS project also addresses the need for innovative and industrial manufacturing processes for the development of robust series of flexible plastronic products. Building on an already established technology as plastic injection, will facilitate a faster uptaking. The advantages of IMHyPE are numerous and include: light weighting, space-saving, robustness, accelerated time-to-market, and high throughput capabilities. It will demonstrate processability, stability, operational lifetime and seamless integration of new products as well as of new technology into traditional goods.Therefore, MADRAS proposes two products for persons’ authentication market and smart manufacturing that will show a step forward towards digitisation and Internet of Things for its contribution to the sustainable deployment of smart products for consumer use. Ethical issues for these matters are properly addressed.Such products belong to the global emerging trend of structural electronics with very large addressable markets as Automotive sector, healthcare and many others. The workplan sets and consolidates the value chain through t
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'The microeconomics of growth across regions in Europe' (EUMICRO).

assistant: **Innovation**

This project is going to enrich the empirics of regional convergence across Europe (Corrado et al 2005; Canova, 2004) which has mainly focussed on country or regional (NUTS2) aggregate growth performance. A new dataset at a smaller geographical scale (NUTS3) for 1031 European regions has been released in September 2005. This is a key element to test for the determinants of growth at the micro-level (Burgess and Venables, 2004) and to examine two of the most important aspects of growth performance which is of particular relevance for the European Commission at this time: the uneven performance of the different NUTS3 regions within each country and the nature of sub-regional spatial externalities and spill-overs. The innovative part of the project is that we will account for aggregation effects using a hierarchical modelling approach.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the concept and methodology overview for 'Fusing Far-Infrared and Near-Infrared Imaging for Pedestrian Injury Mitigation' under Seventh Framework.

assistant: **Concept**

Road accidents involving pedestrians are far more frequent at night than during the day. More than 12 000 pedestrians and cyclists are killed and almost 300 000 are seriously injured in the EU every year. The most important factor is the driver's dramatically reduced range of vision. Fewer pedestrians will be killed or seriously injured through improved driver warning strategies enabled by Night Vision systems with image analysis detecting pedestrians up to 120 m ahead.<br/>There are two types of night-vision technologies on the market: Far-Infrared (FIR) and Near-Infrared (NIR) systems. FIR systems are passive, detecting the thermal radiation at wavelengths in the interval 8-12 µm). NIR systems use a light source with a wavelength of around 0.8 µm to illuminate the object and then detect the reflected light. The main advantage of NIR systems is the picture resolution and that the picture is easy to understand for the driver. FIR systems on the other hand offer a superior range and pedestrian-detection capability. A wide use of both technologies is currently limited by the system cost.<br/>The objective of the project is to demonstrate the next generation Night Vision System with automatic detection of upcoming hazard at an affordable cost. Using a combined NIR/FIR system enable substantial system cost reduction and increased performance through sensor signal fusion. The combined system allow cost reduction through reduced FIR sensor resolution, computing capacity, innovative European technology for molded FIR optics and FIR detectors designed for mass fabrication.<br/>The partners in the consortium represent some of the world's leading organizations in their field of expertise. They also represent different levels in the value chain. Successful completion of the projec
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an executive summary for the EU project 'Multicomponent Synthetic Conjugation: Redefining Chemical Bioconjugation for the Accelerated Production of Next-Generation Antibody-Drug Conjugates in Oncology' (MuSyC) targeting Horizon Europe.

assistant: **Abstract**

Cancer remains one of the leading causes of death worldwide and in Europe in particular. In the continuous fight against this disease, the recent emergence of antibody-drug conjugates (ADCs) has unveiled tremendous hope for the patients. Composed of an antibody that binds cancer cells selectively, ADCs are capable of delivering a cytotoxic drug into tumors selectively, resulting in targeted cell death. Even though a dozen ADCs has already been marketed, they are still extremely expensive and time-consuming to produce. Besides, their development still lacks guiding principles to maximize their efficacy and increase their safety. At the moment, ADCs share the same structural canvas and are produced through the one- or two-step conjugation of antibodies, using a narrow set of linkers and drugs. These limitations represent a major barrier to innovation and to breakthroughs in this yet booming field, preventing the emergence of next-generation ADCs. My proposal to address these challenges is to focus on the bioconjugation step and use it as a chemical step toward the synthesis of valuable motifs. Using a novel chemical approach coined Multicomponent Synthetic Conjugation (MuSyC), I propose to use multicomponent reactions to construct and conjugate valuable motifs at the same time on antibodies, and expand the chemical space of bioconjugation. I will apply this strategy to selected cytotoxic drugs and peptide linkers, in order to streamline the development of the next generation of toxic immunoconjugates. In addition, I will also develop DNA-based tools to guide the discovery of site-selective conjugation reactions. This project will lead to next generations of toxic antibody conjugates, augment the current limited repertoire of approved drugs and linkers, while providing a b
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'Concept and Approach' section for a Seventh Framework proposal on 'Multi-disciplinary University Traditional Health Initiative (MUTHI):Building Sustainable Research Capacity on Plants for Better Public Health in Africa'.

assistant: **Concept**

It is recognised that research must be a basis for better health throughout Africa (e.g. Global Ministerium Forum on Research for Health, Bamako 2008, Beijing declaration 2008). As a consequence It is a priority to build research capacities in the African continent that will set good standards for development of improved health security and systems in the future.  In several African countries western medicine is not widely available, and WHO has recognised the role of traditional medicine and its practitioners in primary health care. The overall objective of this project is to create sustainable research capacity and research networks between the participants in Africa ( Mali, South Africa and Uganda)  collaborating neighbouring institutions, and the European project participants to obtain improved health in Africa. In order to reach this goal we will identify needs and develop and deliver research training programmes. The research institutions from Africa taking part in this project will have implemented research methodologies so that they are able to improve traditional medicines, identify bio-active compounds, and clinically evaluate and register medicinal products that are used for treatment of illnesses that are frequent in African countries.